Bristol Myers Squibb Co. raised its 2024 earnings guidance after reporting better-than-expected revenue and profit, fueled by demand for the blood-thinner Eliquis and several newer treatments.Adjusted ...
This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...
9d
ANSWER: In general, I recommend against stopping prescription medications without your doctor telling you to, and I hope to ...
Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of established ...
The anticlotting drug, Eliquis, has been approved for use in the United States by the country’s regulatory body, the Food and Drug Administration (FDA). Eliquis is manufactured by Bristol-Myers ...
Bristol Myers Squibb’s third-quarter results benefited from sales of its legacy brands Eliquis and Revlimid, as well as ...
More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...
Bristol Myers Squibb posted better-than-expected third-quarter earnings on Thursday citing strong sales of established drugs ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback